Profile data is unavailable for this security.
About the company
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring solutions and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
- Revenue in USD (TTM)20.18bn
- Net income in USD1.71bn
- Incorporated1906
- Employees74.00k
- LocationBecton Dickinson and CoOne Becton DriveFRANKLIN LAKES 07417-1880United StatesUSA
- Phone+1 (201) 847-6800
- Websitehttps://www.bd.com/
Mergers & acquisitions
| Acquired company | BDX:NYQ since announced | Transaction value |
|---|---|---|
| Edwards Lifesciences Corp-Critical Care business | -4.40% | 4.20bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. | 3.84bn | 866.24m | 35.27bn | 11.00k | 41.56 | 21.84 | 35.55 | 9.17 | 10.36 | 10.36 | 46.00 | 19.72 | 1.19 | 3.85 | 7.14 | 349,528.80 | 26.91 | 28.00 | 38.86 | 43.49 | 60.72 | 58.74 | 22.53 | 21.35 | 1.03 | 59.10 | 0.3507 | 0.00 | 8.72 | 10.59 | 24.44 | 17.39 | 1.68 | -- |
| Resmed Inc | 4.81bn | 1.11bn | 35.95bn | 9.98k | 32.47 | 6.92 | 27.88 | 7.48 | 7.54 | 7.54 | 32.59 | 35.39 | 0.6886 | 2.17 | 6.08 | 481,711.90 | 15.94 | 14.24 | 18.11 | 16.53 | 57.67 | 56.85 | 23.15 | 20.35 | 1.91 | 44.71 | 0.1154 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.34 |
| Veeva Systems Inc | 2.57bn | 615.26m | 36.83bn | 7.17k | 59.02 | 7.10 | 56.51 | 14.31 | 3.85 | 3.85 | 15.69 | 32.04 | 0.4453 | -- | 6.27 | 358,846.80 | 10.65 | 11.97 | 12.97 | 15.36 | 73.35 | 72.00 | 23.91 | 23.74 | -- | -- | 0.00 | 0.00 | 9.68 | 22.35 | 7.79 | 18.00 | 21.68 | -- |
| GE HealthCare Technologies Inc | 19.56bn | 1.68bn | 37.96bn | 51.00k | 22.75 | 4.56 | 16.41 | 1.94 | 3.65 | 3.65 | 42.63 | 18.20 | 0.5906 | 5.40 | 4.41 | 383,490.20 | 5.22 | -- | 6.97 | -- | 41.33 | -- | 8.84 | -- | 0.982 | 5.67 | 0.5478 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| Agilent Technologies Inc | 6.51bn | 938.00m | 39.81bn | 17.40k | 43.57 | -- | 35.35 | 6.11 | 3.20 | 3.20 | 22.35 | -- | 0.5759 | 2.96 | 4.98 | -- | 8.30 | -- | 11.90 | -- | 54.49 | -- | 14.41 | -- | 1.58 | 197.63 | 0.365 | -- | -4.73 | 4.75 | -- | -- | 19.36 | 7.80 |
| Edwards Lifesciences Corp | 5.62bn | 1.43bn | 41.60bn | 19.80k | 29.79 | 4.36 | 26.63 | 7.40 | 2.37 | 6.93 | 9.32 | 16.18 | 0.5032 | 1.12 | 7.72 | 283,904.00 | 12.76 | 16.63 | 14.98 | 19.12 | 78.63 | 76.71 | 25.35 | 24.84 | 2.89 | -- | 0.0585 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| Cencora Inc | 293.96bn | 1.51bn | 48.29bn | 42.00k | 33.29 | 75.41 | 18.31 | 0.1643 | 7.51 | 7.51 | 1,467.73 | 3.31 | 4.53 | 15.59 | 12.44 | 6,999,015.00 | 2.34 | 1.12 | 11.57 | 4.84 | 3.33 | 3.24 | 0.5168 | 0.2556 | 0.5291 | 19.37 | 0.848 | 62.15 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
| Becton Dickinson and Co | 20.18bn | 1.71bn | 64.42bn | 74.00k | 38.00 | 2.49 | 16.14 | 3.19 | 5.86 | 5.86 | 69.37 | 89.55 | 0.3667 | 3.10 | 7.25 | 272,675.70 | 3.10 | 2.55 | 3.61 | 2.92 | 45.41 | 45.30 | 8.45 | 7.29 | 0.7397 | 9.09 | 0.4372 | 76.93 | 4.16 | 3.14 | 15.99 | 10.56 | -5.40 | 4.29 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 25.27m | 8.74% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 14.62m | 5.06% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 13.95m | 4.83% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 13.09m | 4.53% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2024 | 8.91m | 3.08% |
| Geode Capital Management LLCas of 30 Sep 2024 | 6.29m | 2.18% |
| Morgan Stanley Investment Management Ltd.as of 30 Sep 2024 | 6.01m | 2.08% |
| Generation Investment Management LLPas of 30 Sep 2024 | 5.95m | 2.06% |
| Massachusetts Financial Services Co.as of 30 Sep 2024 | 5.37m | 1.86% |
| First Eagle Investment Management LLCas of 30 Sep 2024 | 3.37m | 1.17% |
